This clinical trial is focused on studying a type of cancer called relapsed or refractory follicular lymphoma. This is a condition where the cancer has either returned after treatment or has not responded to previous treatments. The study is testing a new treatment combination to see if it is safe and effective. The treatment being studied includes a new medication called Epcoritamab (GEN3013), which is a type of medicine known as a bispecific antibody. This is being tested in combination with two other medications, Rituximab and Lenalidomide, which are already used in treating this type of lymphoma.
The purpose of the study is to compare the effects of the combination of Epcoritamab with Rituximab and Lenalidomide against the effects of Rituximab and Lenalidomide alone. Participants in the study will receive either the new combination treatment or the existing treatment. The study will monitor how well the treatments work and how safe they are for the participants. The study will also look at how long participants live without the cancer getting worse, which is known as progression-free survival.
Participants will be involved in the study for a period of time, during which they will receive the treatments and have regular check-ups to monitor their health and the effects of the treatment. The study aims to provide more information about the potential benefits and risks of adding Epcoritamab to the existing treatment regimen for people with relapsed or refractory follicular lymphoma.
1joining the study
Upon joining the study, eligibility is confirmed based on specific criteria, including a performance status score and the presence of measurable lesions.
The study focuses on individuals with relapsed or refractory follicular lymphoma, a type of blood cancer.
2treatment initiation
The treatment involves a combination of medications: lenalidomide, rituximab, and epcoritamab.
Lenalidomide is administered orally in the form of hard capsules, with dosages of 20 mg and 5 mg.
Rituximab is given through an intravenous infusion, available in concentrations of 100 mg and 500 mg.
Epcoritamab is administered via subcutaneous injection.
3treatment schedule
The treatment is conducted over a specified period, with regular administration of the medications as per the study protocol.
The frequency and duration of each medication are determined by the study guidelines and the participant’s response to treatment.
4monitoring and assessments
Throughout the study, regular monitoring and assessments are conducted to evaluate the safety and effectiveness of the treatment.
Progression-free survival, complete response rates, overall survival, and minimal residual disease negativity are key measures of the study’s success.
5completion of the study
The study is estimated to conclude by June 17, 2030.
Upon completion, the results will contribute to understanding the treatment’s impact on relapsed or refractory follicular lymphoma.
Who Can Join the Study?
The patient must have a performance status score of 0 to 2 according to the Eastern Cooperative Oncology Group (ECOG). This score helps doctors understand how well a patient can perform daily activities.
The patient must have a scan called Fluorodeoxyglucose-positron emission tomography (FDG-PET) that shows a positive lesion, which matches with a computed tomography (CT) or magnetic resonance image (MRI) scan. The patient must have at least one measurable lymph node lesion larger than 1.5 cm or one measurable lesion outside the lymph nodes larger than 1.0 cm on a CT or MRI scan.
The patient must have a confirmed diagnosis of classic follicular lymphoma (FL) at stages II, III, or IV. This means the disease has not changed into a more aggressive type, and the most recent tumor biopsy must show the presence of a protein called CD20.
The patient must have a disease that has come back or not responded to at least one previous treatment that included an anti-CD20 monoclonal antibody combined with chemotherapy. Patients who only had anti-CD20 antibody treatment alone or radiation therapy are not eligible.
The patient must be eligible to receive a treatment called R2, as determined by the study doctor.
The study is open to both male and female patients.
Who Cannot Join the Study?
Patients who have a different type of cancer other than relapsed or refractory follicular lymphoma cannot participate. Relapsed means the cancer has come back after treatment, and refractory means it did not respond to treatment.
Patients who are not within the specified age range for the study cannot participate. The study is open to adults.
Patients who are part of a vulnerable population, such as those unable to give consent, are not eligible.
Patients who have other serious health conditions that might interfere with the study treatment cannot participate.
Patients who are pregnant or breastfeeding are not eligible to participate.
Patients who have had a recent major surgery or are recovering from surgery cannot participate.
Patients who have received certain treatments or medications that might interfere with the study drugs are not eligible.
Patients who have an active infection or other medical conditions that could affect their safety during the study cannot participate.
Epcoritamab is a medication being studied for its potential to help treat follicular lymphoma, a type of blood cancer. It is being tested in combination with other medications to see if it can improve treatment outcomes for patients whose cancer has returned or not responded to previous treatments.
Rituximab is a medication used to treat certain types of cancer, including follicular lymphoma. It works by targeting specific cells in the immune system to help the body fight cancer more effectively.
Lenalidomide is a medication that helps the immune system attack cancer cells. It is used in combination with other treatments to improve the effectiveness of cancer therapy, particularly in cases where the cancer has returned or is resistant to other treatments.
Relapsed and Refractory Follicular Lymphoma – This is a type of non-Hodgkin lymphoma that originates from B-lymphocytes, a kind of white blood cell. It is characterized by the recurrence of the disease after initial treatment (relapsed) or when the disease does not respond to treatment (refractory). Follicular lymphoma typically progresses slowly, often presenting with painless swelling of lymph nodes. Over time, it may spread to other parts of the body, including the bone marrow and spleen. Symptoms can include fatigue, night sweats, and unexplained weight loss. The disease is considered rare and can vary significantly in its progression among different individuals.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Belgium 
Czechia 
Denmark 
France 
Germany 
Greece 
Hungary 
Italy 
Poland 
Slovakia 
Spain 
Sweden 
The Netherlands 